Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708188 | 0.88 | PTGDR2 (0.53) | PTGDR2MAPT | |
| SCHEMBL711478 | 0.88 | PTGDR2 (0.43) | PTGDR2 | |
| SCHEMBL710483 | 0.86 | AKR1B1 (0.42) | PTGDR2AKR1B1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL709244 | 0.79 | PTGDR2 (0.47) | PTGDR2CYP2C9AKR1B1PTGS2 | |
| SCHEMBL710595 | 0.78 | PTGDR2 (0.45) | PTGDR2 | |
| SCHEMBL707811 | 0.77 | PTGDR2 (0.43) | PTGDR2CYP2C9AKR1B1AKR1C3MAPT | |
| SCHEMBL718055 | 0.77 | PTGDR2 (0.50) | PTGDR2MAPT | |
| SCHEMBL711075 | 0.77 | PTGDR2 (0.43) | PTGDR2PTGS2MAPT | |
| SCHEMBL710466 | 0.77 | PTGDR2 (0.46) | PTGDR2 | |
| SCHEMBL711892 | 0.74 | PTGDR2 (0.50) | PTGDR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | claimed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2346807-A1 | NAPHTHYLACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | PTGDR2 39/4885CYP2C9 822/4885AKR1B1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.